Alnylam will likely face challenges in turning a profit this year, despite executives promising to do so. But the label for its newly-approved Amvuttra indication
The FDA on Thursday approved Alnylam’s Amvuttra for a rare heart disease, giving the company an expected yet significant win. Amvuttra is now approved to
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Endo is selling its international pharmaceuticals business to Knight Therapeutics, a Montreal-based specialty pharma company. Endo will get $84 million upfront and could make another
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
A UK startup that wants to bring protein degraders to the neurodegeneration field has closed a $31 million seed round. The company is called Trimtech